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The family of resolvins consists of omega-3 fatty acid-
derived mediators, including E series resolvins gener-
ated from eicosapentaenoic acid (EPA), and carry po-
tent anti-inflammatory properties. Here, we report the
isolation, identification, and bioactions of resolvin E2
(RvE2), which is 5S,18-dihydroxy-eicosapentaenoic
acid. RvE2 stopped zymosan-induced polymorphonu-
clear (PMN) leukocyte infiltration and displayed potent
anti-inflammatory properties in murine peritonitis.
We also demonstrate that human recombinant 5-lipox-
ygenase generates RvE2 from a common precursor
of E series resolvins, namely, 18-hydroxyeicosapen-
taenoate (18-HEPE). Furthermore, the initial 5-hydro-
peroxide intermediate was also converted to a 5(6)-ep-
oxide intermediate in RvE1 formation. These results
demonstrate that RvE2, together with RvE1, may con-
tribute to the beneficial actions of omega-3 fatty acids
in human diseases. Moreover, they indicate that the
5-lipoxygenase in human leukocytes is a pivotal en-
zyme that can produce both pro- and anti-inflamma-
tory chemical mediators.
Introduction
The innate inflammatory response is essential in both
health and disease. This process helps destroy foreign
agents that are potentially harmful to the host and re-
pairs the damaged tissue [1]. Some of the more recent
findings have shown that aberrant inflammation is as-
sociated with a wide range of diseases, including Alz-
heimer’s disease, cardiovascular disease [2], and cystic
fibrosis [3]. These are in addition to the well-appreciated
role of inflammation in diseases such as arthritis and pe-
riodontitis [4]. Because uncontrolled inflammatory re-
sponses can contribute to disease, and the recognition
that resolution of inflammation is an active process
*Correspondence: cnserhan@zeus.bwh.harvard.edu
3 These authors contributed equally to this work.[5, 6], a new area for research has emerged focusing
on promoting resolution as a possible new therapeutic
approach [4, 7–9]. Hence, effective endogenous mecha-
nism(s) that can switch off or dampen, per se, elevated
proinflammatory signals as well as cell trafficking that
can lead to tissue injury and can promote the clearance
of inflammatory cells [7, 8] could be suitable pathways
by which to model novel mimetics.
Along these lines, omega-3 polyunsaturated fatty
acids (PUFAs), such as eicosapentaenoic acid (EPA) or
docosahexaenoic acid (DHA), are widely studied and
have been shown to be associated with beneficial ac-
tions in many inflammatory disorders, including cardio-
vascular disease [10, 11], arthritis, inflammatory bowel
disease, and asthma [12]. These essential PUFAs were
widely believed to potentially act through several possi-
ble mechanisms that include the inhibition of proinflam-
matory eicosanoids and cytokines [13, 14]. Recently, this
laboratory [15] uncovered a novel array of bioactive lipid
mediators present in inflammatory exudates derived
from omega-3 PUFAs [16–19] that carry potent counter-
regulatory and anti-inflammatory actions in vivo in mu-
rine systems. Together, these findings suggest that es-
sential fatty acids are also important in the resolution of
inflammation ([7], and reviewed in [20]). These lipid-de-
rived local chemical mediators are termed resolvins
and protectins [20] and serve as stop signals for neutro-
phil infiltration, a well-appreciated marker cell type in
inflamed tissues [1, 9]. The resolvins (resolution-phase
interaction products) are derived from omega-3 PUFAs,
which, in the presence of aspirin, enable a cyclooxyge-
nase (COX)-2- and lipoxygenase (LO)-mediated conver-
sion of EPA to the 18R series resolvins. The resolvins
were first isolated during the spontaneous resolution
phase of acute inflammation [18, 19], and the potent
bioactive compound 5S,12,18R-trihydroxy-eicosapen-
taenoic acid (EPE) was denoted as resolvin E1 (RvE1).
Recently, we elucidated the complete stereochemistry
of RvE1 (5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-
EPE), and we found that related double bond isomers
are far less potent. Also, a G protein-coupled receptor
with nanomolar (nM) potency for RvE1 [16] was demon-
strated. This RvE1 receptor-ligand interaction displays
potent ability to (1) regulate leukocyte and dendritic cell
trafficking, (2) block IL-12 production, (3) counterregu-
late TNFa-induced NFkB signaling, and (4) protect in
murine colitis [17].
Here, we report the identification of a new bioactive
member of the E series resolvins generated during re-
solvin E1 biosynthesis that shares anti-inflammatory
actions with RvE1. The basic structure of this novel dihy-
droxyeicosanoid was determined and was shown to be
5S,18-dihydroxy-EPE, denoted resolvin E2 (RvE2), the
reduction product of 5S-hydroperoxy,18-hydroxy-EPE
(an intermediate in the biosynthetic pathway of RvE1).
We also document the generation of RvE2 by human
neutrophils and its anti-inflammatory actions in vivo.
Together, these results underscore the pivotal role of
the 5-lipoxygenase in generating both proinflammatory
and anti-inflammatory mediators.
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Resolvins from Eicosapentaenoic Acid, EPAResults and Discussion
Identification of RvE2 in Human Neutrophils
Earlier results from murine exudates obtained during
spontaneous resolution [18, 19] gave novel lipid media-
tors and the proposed biosynthetic pathway of RvE1
(see Figure 1). This led us to hypothesize that 5S,18-
dihydroxy-EPE is formed via reduction of the required
5S-hydroperoxy,18R-hydroxy-EPE, an intermediate in
the biosynthesis of RvE1 [18]. We questioned whether
this compound was formed and carried bioactivity. To
test this, human neutrophils (PMNs) were exposed to
18-HEPE, the endothelial-derived product generated
from EPA [18], with the presence or absence of the diva-
lent cation ionophore (A23187). Figure 2A shows an
HPLC chromatogram of materials isolated from human
PMNs. This chromatogram indicates the presence of
both RvE1 [16] and a 5S,18-dihydroxy-EPE-derived
product that was previously unknown. The chromato-
graphic behavior, i.e., later chromatographic retention
time than RvE1, was also consistent with the presence
of a dihydroxy-containing product. Incubations with
permeabilized PMNs prepared by freeze-thaw dis-
played slightly less conversion of 18-HEPE to RvE1, as
well as formation of the dihydroxy compound (data not
shown). We then assessed whether isolated 5-lipoxyge-
nases could convert 18-HEPE to this new product via
insertion of molecular oxygen at the carbon 5 position.
When analyzed by RP-HPLC, a significant peak at
lmax = 237 nm appeared at an earlier retention time
than 18-HEPE, from human recombinant 5-lipoxyge-
nase incubation (Figure 2B).
After separation via HPLC, the samples were sub-
jected to analysis on LC-UV-MS-MS to establish the
presence of RvE1, as well as to assess the structure of
the compound. The MS-MS spectra (Figure 2B, UV
spectrum insert and structural fragmentation) are con-sistent with a novel 5S,18-dihydroxy-EPE with corre-
sponding fragments at m/z 333 (M-H), 315 (M-H-H2O),
297 (M-H-2H2O), 289 (M-H-CO2), 271 (M-H-H2O-CO2),
and 253 (M-H-2H2O-CO2), as well as diagnostic ions
for carbon 5 and carbon 18 at m/z 303, 275, 257 (275-
H2O), 246, 217, and 115. The UV spectrum of the com-
pound gave a MeOH lmax at 237 nm, consistent with
the presence of a conjugated diene structure that is
distinct from the dual chromophore of RvE1 [16].
LC-UV-MS-MS analysis of the product from enzyme
incubation assigned the major peak as a 5S,18-dihy-
droxy-EPE and an 8,18-dihydroxy-EPE as a minor prod-
uct (data not shown). The fragmentation pattern of
5S,18-dihydroxy-EPE was essentially identical to that
obtained from human PMN incubations (Figure 2B). Po-
tato 5-LO also generated the same 5,18-diHEPE, which
was confirmed with tandem MS fragmentation pattern
comparison (data not shown). We next isolated the novel
5,18-diHEPE to assess its potential biological activity
compared to RvE1.
RvE2 Reduces Neutrophil Infiltration
in Murine Peritonitis
To determine the potential biologic properties of RvE2,
we isolated the compound as described in the legend
of Figure 2 and compared it to RvE1 in a widely used
model of murine peritonitis (Figure 3). Because of the
potent bioactions and anti-inflammatory properties of
RvE1 [16–18], we intravenously treated mice separately
with RvE1 and RvE2 as a comparative side-by-side anal-
ysis of the potency of RvE2. When used intravenously,
very low doses of RvE1, at only 1 ng per mouse, stopped
PMN infiltration by 15.1% 6 5.7% and 19.8% 6 3.2%
and by 44.5% 6 3.2% at 10 and 100 ng per mouse, re-
spectively (Figure 3). A direct side-by-side comparison
showed that RvE2 reduced PMN infiltration by 11.3% 6
4.8%, 17.7% 6 9.9%, and 33.7% 6 5.0% at 1, 10, and
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1195Figure 2. Generation of diHEPEs from Cell and Enzymatic Incubations
(A) RP-HPLC chromatogram of the 18-HEPE incubation product with human PMN (upper plot) and human recombinant 5-LO (lower plot),
monitored with UV absorbance at 237 nm.
(B) UV and tandem mass spectra of major products isolated from human PMN (upper) and human recombinant 5-LO (lower) incubation,
assigned as 5,18-diHEPE. See Experimental Procedures for conditions of analysis with LC-UV-MS-MS.100 ng, respectively. RvE2 was not significantly different
than RvE1 at any of the doses (p > 0.05). Both RvE1 and
RvE2 significantly reduced PMN infiltration in zymosan-
treated mice (p < 0.05) and were additive when given to-
gether (Figure 3B). In order to assess the mode of action
of RvE2, we next compared two different routes of ad-
ministration. At 10 ng dose per mouse, RvE2 was active
via both tail vein (intravenous administration) and via
intraperitoneal injection, reducing PMN infiltration by
47.6% 6 6.6% and 34.5% 6 4.5%, respectively (Fig-
ure 3C). For the purpose of direct comparison, RvE1 atthese doses did not significantly stop PMN recruitment
when administrated intraperitoneally, while it displayed
potent actions when administered intravenously. Similar
results were obtained with RvE1 when administered
in either its free acid or carboxylic methyl ester form
(Figure 3D).
Biosynthesis via 5(6)-Epoxide EPE Intermediate
and Trihydroxy-EPEs
When 18-HEPE was incubated with human recombinant
5-LO, several compounds carrying dual chromophores
Chemistry & Biology
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At t = 0, 1 mg Zymosan A was injected into mouse peritoneum, immediately followed by intravenous or intraperitoneal injection of resolvin E1
or resolvin E2. After 2 hr, mice were euthanized and peritonea were lavaged with DPBS. The number of PMN infiltrated was enumerated, and
percent changes were determined.
(A) Direct comparison between resolvin E1 (black) and resolvin E2 (gray) at 1, 10, 100 ng doses administered intravenously.
(B) Additive bioaction of resolvin E1 and resolvin E2. With the same procedure as that described in (A), 10 ng RvE1, 10 ng RvE2, or 10 ng of
each compound were administered intravenously.
(C) Comparison of RvE2 bioaction when administered intravenously and intraperitoneally. A total of 10 ng RvE2 was delivered intravenously or
intraperitoneally.
(D) Dose-response curve of RvE1 intraperitoneal administration. 1, 10, 100, and 1000 ng RvE1 methyl ester were delivered into the peritoneum.
Inset; 10 ng RvE1 (black) or RvE2 (gray) was delivered intraperitoneally. Results are the mean 6 SEM, nR 3 at each dose of RvE1 or RvE2 for
all values. *, p < 0.02; **, p < 0.001.of diene-triene structure (cf. [18]) were evident in UV-RP-
HPLC analyses. Eluting earlier than confirmed dihy-
droxy-EPEs, these possible trihydroxy-EPE isomers
are categorized as (1) multiple peaks with identical,
dual chromophores at 235 nm and 269 nm, eluted at a
retention time of 10.5–12.0 min (compound I) and as (2)
a single peak with dual chromophores at 235 nm and
275 nm, eluted at 17 min (see Figure 4A) (compound
II). With LC-UV-MS-MS analysis, the former is identified
as 5,12,18-trihydroxy-EPE, and the latter as 5,6,18-trihy-
droxy-EPE.
The MS-MS spectrum (Figure 4B, UV spectrum insert
and structural fragmentation) of compound I is assigned
as 5,12,18-trihydroxy-EPE, with corresponding frag-
ments at m/z 349 (M-H), 331 (M-H-H2O), 313 (M-H-
2H2O), 305 (M-H-CO2), 295 (M-H-3H2O), as well as diag-nostic ions for fragmentation at carbons 12 and 18 at
m/z 195 and 291, respectively. Similar neutral loss frag-
ments were identified from the tandem MS spectrum of
compound II (Figure 4C), with additional diagnostic frag-
ments for the vicinal diol at m/z 233 and 203. In addition,
the presence of a triene chromophore with a triplet ab-
sorption of lmax = w275 nm assigned compound II’s
structure as 5,6,18-trihydroxy-EPE. Despite similar tan-
dem mass spectra to RvE1, the 5,12,18-trihydroxy-EPE
obtained from enzymatic incubations was considered
the likely nonenzymatic hydrolysis products of a 5(6)-ep-
oxide intermediate bearing a 6-trans configuration. This
is supported by the fact that (1) this product bears a
slightly shorter lmax (269 nm), which is characteristic
of a synthetic 5,12-all-trans-conjugated triene of RvE1
[16], and the fact that (2) none of these products
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(A) UV chromatogram of dual chromophore-containing compounds. Incubation products were analyzed with the same conditions used for
diHEPEs on RP-HPLC (see Figure 2 and Experimental Procedures for detailed conditions). I represents four peaks bearing diene-triene
dual chromophores at 235 nm and 269 nm, respectively. II represents a single peak bearing diene at 235 nm and elongated triene chromophore
at 275 nm.
(B) LC-UV-MS-MS analysis result of I, assigned as 5,12,18-trihydroxy-EPE.
(C) LC-UV-MS-MS analysis result of II, assigned as 5,6,18-trihydroxy-EPE.coeluted with synthetic RvE1 [18], which carries the 6-
cis double bond critical for its potent bioactivity (data
not shown).
Acidic methanol trapping and work-up gave a major
peak at 15.9 min (Figure 5B), which showed diagnostic
ions consistent with 12-methoxy-5S,18-dihydroxy-EPE.
The minor peak at 20.5 min is likely a 6-methoxy-5S,
18-dihydroxy-EPE, although not enough diagnostic
fragmentations were present to assign its structure.
RvE2 Production by Human PMNs in Hypoxia
In normal oxygen levels, zymosan treatment did not ap-
parently alter RvE2 generation by PMNs. Of interest,
PMNs exposed to the phagocytic stimulus in hypoxic
conditions showed a tendency to produce more RvE2(Table 1) vide infra. However, this increase did not prove
to be statistically significant.
The results from this report indicate that RvE2 exhibits
potent anti-inflammatory properties similar to those of
RvE1. RvE2 stops PMN infiltration in vivo at near the po-
tency level of RvE1, which was in the nanogram range
in vivo. The present findings also demonstrate that RvE2
is generated in vivo and thus may act as an endogenous
anti-inflammatory mediator generated from EPA. When
directly compared to RvE1 generation, greater amounts
of the initial 5-hydroperoxide are reduced to RvE2 in in-
cubations with human leukocytes carried out in hypoxic
conditions (Figure 2 and Table 1). A hypoxic local envi-
ronment is encountered at local sites of inflammation,
within exudates, and during ischemic reperfusion injury
Chemistry & Biology
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(A) Proposed mechanism of acidic O-methoxy product generation. In acidic conditions, 5S(6)-epoxide is protonated and opened to become
a carbocation intermediate. Excess MeOH concentration (MeOH:H2O w10:1 in this procedure) prefers the addition of a methoxy group to
carbocation. Stereochemically favored, the 1,8 addition to produce the 12-methoxy adduct is the major product (MW = 364).
(B) Selective ion chromatogram at m/z 363 with LC-UV-MS-MS and UV spectrum of a peak at a retention time of 15.9 min on this chromato-
gram.
(C) Tandem mass spectrum of the peak eluted at 15.9 min.of second organs [1]. In hypoxia chambers, human vas-
cular endothelial cells that were treated with aspirin
avidly converted extracellular sources of EPA to 18-
HEPE, which is further transformed to RvE1 (Figure 1)
by activated human leukocytes [18]. In the present ex-
periments, the hypoxic environment with activated hu-
man leukocytes gave a trend toward enhanced biosyn-
thesis of RvE2 (Table 1). Hence, regulated production
of RvE1 and RvE2 might still maintain the overall anti-in-
flammatory activity of this biosynthetic pathway withEPA as a substrate. Because of its protective anti-inflam-
matory in vivo action and significant quantities relative to
those of RvE1, RvE2 may also share with RvE1 the key
regulator role during resolution of this biosynthetic cir-
cuit of acute inflammation. Also, as demonstrated here,
the anti-inflammatory properties of RvE2 were similar
to those of RvE1 when given by intravenous administra-
tion. Of interest, when delivered directly to the site of in-
flammation (intraperitoneally), RvE2 also reduces PMN
infiltration and, at equal doses, proved more potent
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intraperitoneally. These results suggest that RvE2 has
specific target cell types that are distinct from those of
RvE1.
Results of the present report demonstrate the identity
and structure of RvE2 by using physical methods such
as UV spectrometry and MS-MS analyses of the gener-
ated products from neutrophil incubations. Earlier re-
sults [21] demonstrate that 5-lipoxygenase, with EPA
as a substrate, promotes oxygenation at the carbon 5
position of EPA and inserts molecular oxygen in as the
S configuration [22]. To establish the structural compo-
nents of RvE2, we examined in vitro generation with iso-
lated 5-LO and 18-HEPE and documented the insertion
of oxygen into the carbon 5 position generating the 5S
alcohol group in RvE2. During incubations with isolated
human recombinant 5-LO, we also obtained both
5,12,18-triHEPE and 5,6,18-triHEPE, which were formed
via aqueous hydrolysis of a 5(6)-epoxide-containing
intermediate (see Figure 6). Along with confirming the
formation of an epoxide-containing intermediate, we
confirmed that human 5-LO also serves as an epoxide
synthase in the E series resolvin pathways. It is notewor-
thy that RvE1 was identified only with human leukocyte
incubations and was not obtained in substantial
amounts with isolated recombinant 5-LO. These find-
ings strongly indicate that enzymatic hydrolysis of the
epoxide intermediate is required for the generation of
the potent RvE1 that carries the correct double bond ge-
ometry and chirality for the carbon-12-position alcohol.
The epoxide-containing intermediate’s hydrolysis to
RvE1 requires changing from trans to 6-cis regiochemis-
try, a reaction that likely requires a specific enzyme (see
Figure 6B and cf. [16]).
These lipid mediators, namely, resolvins and protec-
tins, actively regulate the resolution of inflammation via
novel molecular circuits [7]. As reported here, the anti-in-
flammatory properties of RvE2 are slightly less potent
than those of RvE1, but they are still in the nanomolar
range. Thus, it is likely that these lipid mediators, namely,
E series resolvins from EPA, may provide a basis for en-
dogenous protection against an aberrant or uncontrolled
innate inflammatory response, as well as provide a mo-
lecular basis for the beneficial actions of EPA and fish
oils noted in human studies. Given the nature of the dihy-
droxy-EPE products identified here, RvE2 may be partic-
Table 1. RvE1 and RvE2 Generation by Human PMNs in Normoxic
and Hypoxic Environments
Incubation Conditiona RvE1, ng RvE2, ng
Normoxic PMN 0.29 8.05
Normoxic PMN treated with zymosan 0.11 8.15
Hypoxic PMN 0.17 7.61
Hypoxic PMN treated with zymosan 0.12 10.86
Without PMN 0.00 0.00
a Results are from human PMN incubations, representative of n = 3
separate donors. PMNs were isolated from human whole blood
and were incubated with 5 mg 18-HEPE or activated first with zymo-
san (100 mg/1 ml) and then incubated with 18-HEPE (5 mg, 37C, 30
min [pH 7.45]). The same procedures were carried out in parallel in
a hypoxia chamber (see Experimental Procedures). After incuba-
tions, products were extracted, identified, and quantified by using
internal standard and LC-MS-MS-based analysis.ularly attractive because of the ease of its synthesis as
well as its potent bioactions in regulating inflammation.
Taken together, the generation of RvE2 in vivo and
in vitro provides evidence for a novel lipid mediator de-
rived from EPA and human neutrophils that carry anti-
inflammatory properties and the biosynthesis of RvE2
and RvE1 as bioactive mediators generated from the
omega-3 fatty acid EPA.
The contribution of 5-LO to biosynthesis of anti-in-
flammatory mediators such as E series resolvins sug-
gests potential protective roles of this lipoxygenase in
addition to its widely appreciated role in leukotriene bio-
synthesis and production of proinflammatory mediators
[8, 9]. This result is consistent with recent reports that
document exacerbated inflammatory responses in 5-
LO-deficient mice in several disease models. These in-
clude more severe disease in EAE (experimental allergic
encephalomyelitis) in 5-LO-deficient mice [23] and ele-
vated inflammatory cytokine production in tuberculosis
[24], which indicate that 5-LO can produce protective
mediators in situ that may include lipoxins and resolvins.
Thus, as a therapeutic approach, inhibitors of 5-LO may
not come without unwanted side effects; recent con-
cerns have been raised regarding adverse effects with
COX-2 inhibitors [25]. The overall pro- or anti-inflamma-
tory role(s) of 5-LO appears to be determined via sub-
strate availability (i.e., arachidonic acid for leukotrienes
or EPA converted to E series resolvins) during the time
course of an inflammatory response. Hence, it might
be useful to consider resolvins such as RvE2 as endog-
enous agonists of anti-inflammation and as potential
new therapeutics.
Significance
Omega-3 PUFAs are considered to be beneficial in hu-
man health and disease. However, the molecular basis
of EPA’s anti-inflammatory actions still remains of in-
terest. Results of the present study demonstrate the
identification and potent bioactions of resolvin E2, a
newly characterized member of the recently uncov-
ered EPA-derived pathways that generate anti-inflam-
matory chemical mediators termed resolvins. Human
5-lipoxygenase is demonstrated here to be a pivotal
enzyme in the conversion of EPA to these potent, ac-
tive mediators, by catalyzing the initial 5-hydroperox-
ide generation of 18-hydroxy-eicosapentaenoic acid
and its subsequent 5S(6)-epoxidation, two steps that
are essential in resolvin E1 biosynthesis. Resolvin
E2was equipotent to the originalmember, intravenous
resolvin E1, and was additive at low doses, indicating
two separate anti-inflammatory cascades. Human neu-
trophils biosynthesized RvE2 in greater amounts than
RvE1, suggesting a significant role for RvE2, which
now provides anti-inflammatory approaches that




Human whole (venous) blood (60 ml) was collected with heparin from
healthy volunteers (who declined taking medication for at least 2
weeks before donation; Brigham and Women’s Hospital protocol
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(A) The 5-LO biosynthesizes the 5(6)-epoxy intermediate, which can be nonenzymatically hydrolyzed to all-trans isomers depicted here. The
epoxide intermediate can be identified by acidic methanol trapping (see text).
(B) Human 5-lipoxygenase in the biosynthesis of both resolvin E1 and resolvin E2, potent anti-inflammatory lipid mediators.88-02642). Human neutrophils (PMNs) were freshly isolated from the
whole blood by Ficoll gradient and were enumerated as described in
[19]. PMNs were also permeabilized by using rapid freezing in a dry
ice-isopropanol bath, were thawed to room temperature, and were
taken immediately for incubations, as described in [26]. Both intact
and permeabilized PMNs were used within 2 hr of isolation.
Human Neutrophil Incubations
PMNs were divided into 50 3 106 cells in 1 ml DPBS with Ca2+ and
Mg2+. Intact PMNs were incubated with 18R/S-HEPE (16 mg, Cay-
man Chemical) and with or without calcium ionophore (A23187, 2.5
mM), while permeabilized PMNs were incubated with 18R/S-HEPE
(16 mg, Cayman Chemical) and with or without ATP (Sigma-Aldrich,
1 mM). All incubations were carried out for 30 min in a 37C water
bath and were then stopped with two volumes of cold methanol.Human PMN Incubations in a Hypoxic Environment
PMNs for hypoxia experiments were separated into 103 106 cells in
0.5 ml DPBS with Ca2+ and Mg2+. Media for hypoxia incubations
were preconditioned for 24 hr in a hypoxic chamber (COY laboratory
products), with 1% oxygen with nitrogen, carbon dioxide (5%), and
water vapor. Cells were conditioned (37C/5% CO2) for 60 min at pH
7.45 in an incubator at normoxic conditions or in a hypoxic chamber.
Cells were then incubated for 30 min with 5 mg EPA (Cayman Chem-
ical) or 18-HEPE or were activated first with 50 mg zymosan (Sigma-
Aldrich) and then incubated with substrate. The reactions were
stopped with two volumes of ice-cold methanol.
Enzymatic Conversion of 18-HEPE with Human 5-Lipoxygenase
Potato or human recombinant 5-lipoxygenase (Cayman Chemical)
was incubated with 18R/S-HEPE (Cayman Chemical) at 37C, in
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the reaction was quenched with two volumes of cold MeOH, and
hydroperoxide intermediates were reduced with excess NaBH4.
MeOH Trapping
The reaction mixture was poured on 103 volume of acidic ice-cold
methanol (pH 3 after mixing) containing d5-PGE2 as an internal stan-
dard. A total of 5 min later, this acidic methanol solution was diluted
with 5 ml MiliQ water, the pH was adjusted to 3.5, and the sample
was directly loaded on a solid-phase extraction column.
High-Pressure Liquid Chromatography and LC-MS-MS Analysis
Incubations were extracted along with an internal standard, by using
C18 solid-phase extraction (Alltech Associates). To separate and
quantify conversion products of 18-HEPE, RP-HPLC was carried
out by using a 1100 series liquid chromatography system (Agilent)
with a reverse-phase Luna C18(2) column with dimensions of 150
mm 3 2 mm 3 5 mm (Phenomenex). A gradient from 55:45:0.01 to
85:15:0.01 (MeOH:H2O:acetic acid) was used as the mobile phase.
Tandem MS-based structure analysis of lipid mediators was per-
formed to determine the production of methanol-trapped products
and other 18-HEPE-derived oxygenated products by using a Finni-
gan LCQ liquid chromatography ion trap tandem mass spectrometer
(San Jose, CA) equipped with a Luna C18(2) (100 mm 3 2 mm 3 5
mm) column, and a photodiode array detector that monitored UV ab-
sorbancew0.1–0.2 min before samples entered the MS-MS [7].
Murine Peritonitis
Peritonitis was performed with 6- to 8-week-old FVB male mice
(Charles River Laboratories) fed laboratory Rodent Diet 5001 (Purina
Mills). After anesthetization with isoflurane, compounds or vehicle
was administered intravenously via tail vein injections or intraperito-
neally. Each test compound or vehicle alone was suspended in 5 ml
ethanol, mixed in 120 ml sterile saline, and rapidly injected either
intravenously or intraperitoneally. Zymosan A (Sigma-Aldrich) was
suspended in 1 ml saline (1 mg/ml) and injected intraperitoneally im-
mediately following compound administration. A total of 2 hr after
the zymosan injection, in accordance with Harvard Medical Area
Standing Committee on Animals protocol no. 02570, mice were sac-
rificed with an overdose of isoflurane. Peritoneal lavages were col-
lected and enumerated via light microscopy. Differential leukocyte
counts were performed by using a modified Wright-Giemsa stain
(Sigma-Aldrich) and were differentiated via light microscopy.
Statistical Analysis
All results in the figures and text are expressed as mean 6 SEM of
n R 3 mice per group. Statistical significance was determined by
Student’s t test; p < 0.05 was considered significant.
Acknowledgments
We thank M.H. Small and Stacey Lindberg for assistance with man-
uscript preparation and Timothy F. Porter and Tamara Baer for tech-
nical assistance with murine protocols. The present studies were
supported by National Institutes of Health grants P50-DE016191
and GM38765. C.N.S. is a consultant for the clinical development
of lipoxin stable analogs with Berlex-Schering AG and Resolvyx
Pharmaceuticals for development of resolvin E1.
Received: June 8, 2006
Revised: August 21, 2006
Accepted: September 14, 2006
Published: November 27, 2006
References
1. Majno, G., and Joris, I. (2004). Cells, Tissues, and Disease: Prin-
ciples of General Pathology, Second Edition (New York: Oxford
University Press).
2. Nathan, C. (2002). Points of control in inflammation. Nature 420,
846–852.
3. Karp, C.L., Flick, L.M., Park, K.W., Softic, S., Greer, T.M., Keled-
jian, R., Yang, R., Uddin, J., Guggino, W.B., Atabani, S.F., et al.(2004). Defective lipoxin-mediated anti-inflammatory activity in
the cystic fibrosis airway. Nat. Immunol. 5, 388–392.
4. Van Dyke, T.E., and Serhan, C.N. (2003). Resolution of inflamma-
tion: a new paradigm for the pathogenesis of periodontal dis-
eases. J. Dent. Res. 82, 82–90.
5. Levy, B.D., Petasis, N.A., and Serhan, C.N. (1997). A role for pol-
yisoprenyl phosphates in intracellular signaling. Nature 389,
985–990.
6. Serhan, C.N. (1994). Lipoxin biosynthesis and its impact in in-
flammatory and vascular events. Biochim. Biophys. Acta 1212,
1–25.
7. Bannenberg, G.L., Chiang, N., Ariel, A., Arita, M., Tjonahen, E.,
Gotlinger, K.H., Hong, S., and Serhan, C.N. (2005). Molecular
circuits of resolution: formation and actions of resolvins and
protectins. J. Immunol. 174, 4345–4355.
8. Gilroy, D.W., Lawrence, T., Perretti, M., and Rossi, A.G. (2004).
Inflammatory resolution: new opportunities for drug discovery.
Nat. Rev. Drug Discov. 3, 401–416.
9. Lawrence, T., Willoughby, D.A., and Gilroy, D.W. (2002). Anti-
inflammatory lipid mediators and insights into the resolution of
inflammation. Nat. Rev. Immunol. 2, 787–795.
10. Albert, C.M., Campos, H., Stampfer, M.J., Ridker, P.M., Manson,
J.E., Willett, W.C., and Ma, J. (2002). Blood levels of long-chain
n-3 fatty acids and the risk of sudden death. N. Engl. J. Med.
346, 1113–1118.
11. GISSI-Prevenzione Investigators (1999). Dietary supplementa-
tion with n-3 polyunsaturated fatty acids and vitamin E after
myocardial infarction: results of the GISSI-Prevenzione trial.
Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto
miocardico. Lancet 354, 447–455.
12. Simopoulos, A.P. (2002). Omega-3 fatty acids in inflammation
and autoimmune diseases. J. Am. Coll. Nutr. 21, 495–505.
13. Calder, P.C. (2001). Polyunsaturated fatty acids, inflammation,
and immunity. Lipids 36, 1007–1024.
14. Lands, W.E.M. (2003). Diets could prevent many diseases.
Lipids 38, 317–321.
15. Serhan, C.N. June 2004. Resolvins: biotemplates for novel ther-
apeutic interventions. U.S. patent US2004/0116408 A1. Filed
August 12, 2003.
16. Arita, M., Bianchini, F., Aliberti, J., Sher, A., Chiang, N., Hong, S.,
Yang, R., Petasis, N.A., and Serhan, C.N. (2005). Stereochemical
assignment, anti-inflammatory properties, and receptor for the
omega-3 lipid mediator resolvin E1. J. Exp. Med. 201, 713–722.
17. Arita, M., Yoshida, M., Hong, S., Tjonahen, E., Glickman, J.N.,
Petasis, N.A., Blumberg, R.S., and Serhan, C.N. (2005). Resolvin
E1, a novel endogenous lipid mediator derived from omega-3
eicosapentaenoic acid, protects against TNBS-induced colitis.
Proc. Natl. Acad. Sci. USA 102, 7671–7676.
18. Serhan, C.N., Clish, C.B., Brannon, J., Colgan, S.P., Chiang, N.,
and Gronert, K. (2000). Novel functional sets of lipid-derived me-
diators with antiinflammatory actions generated from omega-3
fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory
drugs and transcellular processing. J. Exp. Med. 192, 1197–
1204.
19. Serhan, C.N., Hong, S., Gronert, K., Colgan, S.P., Devchand,
P.R., Mirick, G., and Moussignac, R.L. (2002). Resolvins: a family
of bioactive products of omega-3 fatty acid transformation cir-
cuits initiated by aspirin treatment that counter pro-inflamma-
tion signals. J. Exp. Med. 196, 1025–1037.
20. Serhan, C.N. (2004). Novel omega-3-derived local mediators in
anti-inflammation and resolution. Pharmacol. Ther. 105, 7–21.
21. Ochi, K., Yoshimoto, T., Yamamoto, S., Taniguchi, K., and Miya-
moto, T. (1983). Arachidonate 5-lipoxygenase of guinea pig peri-
toneal polymorphonuclear leukocytes. Activation by adenosine
50-triphosphate. J. Biol. Chem. 258, 5754–5758.
22. Ueda, N., Kaneko, S., Yoshimoto, T., and Yamamoto, S. (1986).
Purification of arachidonate 5-lipoxygenase from porcine leuko-
cytes and its reactivity with hydroperoxyeicosatetraenoic acids.
J. Biol. Chem. 261, 7982–7988.
23. Emerson, M.R., and LeVine, S.M. (2004). Experimental allergic
encephalomyelitis is exacerbated in mice deficient for 12/15-
lipoxygenase or 5-lipoxygenase. Brain Res. 17, 140–145.
24. Bafica, A., Scanga, C.A., Serhan, C., Machado, F., White, S.,
Sher, A., and Aliberti, J. (2005). Host control of Mycobacterium
Chemistry & Biology
1202tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin
production. J. Clin. Invest. 115, 1601–1606.
25. Grosser, T., Fries, S., and FitzGerald, G.A. (2006). Biological ba-
sis for the cardiovascular consequences of COX-2 inhibition:
therapeutic challenges and opportunities. J. Clin. Invest. 116,
4–15.
26. Romano, M., and Serhan, C.N. (1992). Lipoxin generation by per-
meabilized human platelets. Biochemistry 31, 8269–8277.
27. Shimizu, T., Ra˚dmark, O., and Samuelsson, B. (1984). Enzyme
with dual lipoxygenase activites catalyzes leukotriene A4 syn-
thesis from arachidonic acid. Proc. Natl. Acad. Sci. USA 81,
689–693.
